Triveni Secures $65 Million in Latest Series C Funding Round

Triveni secured $65 million in its latest Series C, adding another data point to the Healthcare & Life Sciences funding market.

Triveni Raises $65 million in Funding

Triveni closes $65m Series C to advance bispecific eczema candidate. TRIV-573 is a bispecific antibody designed to block both KLK5/7, a pair of proteases implicated in skin barrier breakdown, and the Th2 cytokine IL-13.

Investors Behind the Funding

The round was backed by the University of Warwick, she currently reports on the latest in the partnering, investment space, as well as drug modalities. Capvizr tracks this investor activity alongside sector momentum, co-investor patterns, and recent comparable raises.

Company Profile and Market Context

Triveni operates in Healthcare & Life Sciences. Triveni's Series C round shows investors are still backing digital health platforms with real scale narratives. At $65M, the deal suggests buyers want category leaders that can turn AI, automation, or workflow leverage into durable enterprise demand.

Strategic Use of Funds

advance bispecific eczema candidate

Looking Ahead

Triveni closes $65m Series C to advance bispecific eczema candidate

Source reference: original announcement/article.